BTIG, a leading investment firm, has revealed its top healthcare picks for the second half of 2023. Among the selected…
Browsing: clinical trials
BTIG, a leading financial services firm, has recently revealed its top healthcare picks for the second half of 2023. Among…
The FDA’s recent approval of Lundbeck-Otsuka’s Rexulti marks a significant milestone in Alzheimer’s disease treatment[1]. The medication has been specifically…
MorphoSys, the German biotech company, has delivered positive news to its shareholders. The Phase 3 myelofibrosis program is progressing 16%…
Roche’s Alzheimer’s drug Gantenerumab has experienced a major setback. It failed phase 3 clinical trials, resulting in financial losses for…
MorphoSys is on track to complete its Phase 3 myelofibrosis program 16% faster than originally planned. [1] However, there is…
In a highly anticipated move, JP Morgan analyst Michael Nuen suggests that MorphoSys, the German biotech company, could experience a…
Durham-based company Humacyte experienced a significant boost in its stock prices, surging by 10 percent. Following a remarkable $160 million…
NewRegen, Inc. (NREG) has emerged as a leading force in the regenerative medicine industry, propelling significant growth in the health…